ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ: ARWR
▲
33.61
+0.33
+0.99%
1 Day
-
Open
33.29
-
Previous Close
33.28
-
Volume (Avg)
427.16k (1.12M)
-
Day's Range
33.21-34.08
-
52Wk Range
26.81-56.25
-
Market Cap.
3.56B
-
Dividend Rate ( Yield)
-
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
446.20 (-)
Top Stories
-
Meet Jennifer Garner's Boyfriend John Miller
Town and Country 4 days ago -
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
YAHOO!Finance -
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Yahoo Finance -
ARWR Arrowhead Pharmaceuticals, Inc.
Seeking Alpha -
Arrowhead Pharmaceuticals Inc. News
TheStreet.com 12/14/2022Auris Medical says it will advance a treatment for colorectal cancer as its first therapeutic indication for a delivery platform. Arrowhead's move comes after a toxicology study in rats contained ...
-
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Yahoo -
Arrowhead Pharmaceuticals Corp.
Barron's -
Analysts Say You Should Still Hold Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)
stocksregister -
Arrowhead Pharmaceuticals Pauses Test of its Cystic Fibrosis Treatment
TheStreet.com -
Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
newsroom.businesswire.com -
Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Morningstar%2c Inc. -
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)’s Stock Adds 1.85%, Making It A Good Investment
stocksregister -
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Morningstar%2c Inc. -
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Yahoo News -
Arrowhead Pharmaceuticals Inc. (ARWR): Skating on Thin Ice? We Know the Answer
newsheater 11/30/2022Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) went down by -3.14% from its latest closing price compared to the recent 1-year high of $56.25. The company’s stock price has collected -11.19% of loss in the last five trading sessions.
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
The Globe and Mail -
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Yahoo -
Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR)
Nasdaq
